DK3290513T3 - Sammensætninger og fremgangsmåder til forhindring af aav-vektoraggregering - Google Patents

Sammensætninger og fremgangsmåder til forhindring af aav-vektoraggregering Download PDF

Info

Publication number
DK3290513T3
DK3290513T3 DK17186206.3T DK17186206T DK3290513T3 DK 3290513 T3 DK3290513 T3 DK 3290513T3 DK 17186206 T DK17186206 T DK 17186206T DK 3290513 T3 DK3290513 T3 DK 3290513T3
Authority
DK
Denmark
Prior art keywords
compositions
preventing
methods
aav vector
vector aggregation
Prior art date
Application number
DK17186206.3T
Other languages
English (en)
Inventor
John Fraser Wright
Guang Qu
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35462907&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3290513(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Application granted granted Critical
Publication of DK3290513T3 publication Critical patent/DK3290513T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Lubricants (AREA)
  • Curing Cements, Concrete, And Artificial Stone (AREA)
DK17186206.3T 2004-06-01 2005-06-01 Sammensætninger og fremgangsmåder til forhindring af aav-vektoraggregering DK3290513T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57599704P 2004-06-01 2004-06-01
US63922204P 2004-12-22 2004-12-22
EP05755269.7A EP1751275B1 (en) 2004-06-01 2005-06-01 Compositions and methods to prevent aav vector aggregation

Publications (1)

Publication Number Publication Date
DK3290513T3 true DK3290513T3 (da) 2022-12-12

Family

ID=35462907

Family Applications (2)

Application Number Title Priority Date Filing Date
DK17186206.3T DK3290513T3 (da) 2004-06-01 2005-06-01 Sammensætninger og fremgangsmåder til forhindring af aav-vektoraggregering
DK05755269.7T DK1751275T3 (da) 2004-06-01 2005-06-01 Sammensætninger og fremgangsmåder til forebyggelse af aggregering af aav-vektorer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK05755269.7T DK1751275T3 (da) 2004-06-01 2005-06-01 Sammensætninger og fremgangsmåder til forebyggelse af aggregering af aav-vektorer

Country Status (11)

Country Link
US (4) US7704721B2 (da)
EP (3) EP3290513B1 (da)
JP (5) JP2008501339A (da)
BR (1) BRPI0511764B8 (da)
CA (1) CA2569244C (da)
CY (1) CY1125798T1 (da)
DK (2) DK3290513T3 (da)
ES (2) ES2647477T3 (da)
HU (2) HUE035418T2 (da)
MX (3) MX360727B (da)
WO (1) WO2005118792A1 (da)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2668417A1 (en) * 2006-11-03 2008-05-15 Alphavax, Inc. Alphavirus and alphavirus replicon particle formulations and methods
US20090111099A1 (en) * 2007-10-27 2009-04-30 Yongsheng Ma Promoter Detection and Analysis
US8067241B2 (en) * 2009-08-26 2011-11-29 General Electric Company Method and apparatus for antigen retrieval process
ES2680915T3 (es) * 2010-01-28 2018-09-11 The Children's Hospital Of Philadelphia Plataforma de fabricación escalable para la purificación de vectores virales y vectores virales purificados de este modo para su utilización en terapia génica
JP2013523175A (ja) 2010-04-14 2013-06-17 イーエムディー・ミリポア・コーポレーション 高力価、高純度のウイルスストックの作製方法及びその使用方法
WO2012018628A1 (en) 2010-07-26 2012-02-09 Board Of Regents, The University Of Texas System Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine
WO2012122625A1 (en) * 2011-03-14 2012-09-20 National Research Council Of Canada Method of viral production in cells
CA2856137A1 (en) 2011-11-22 2013-05-30 The Children's Hospital Of Philadelphia Virus vectors for highly efficient transgene delivery
WO2013090409A1 (en) 2011-12-12 2013-06-20 The Children's Hospital Of Philadelphia Large commercial scale lentiviral vector production system and vectors produced thereby
US9974850B2 (en) 2013-01-25 2018-05-22 Board Of Regents, The University Of Texas System Immunogenic compositions and uses thereof
PT3010537T (pt) * 2013-06-17 2019-12-03 De Staat Der Nederlanden Vert Door De Mini Van Vws Miniie Van Volksgezondheid Welzijn En Sport Métodos para a prevenção da agregação de componentes virais
CN105765066B (zh) * 2013-11-29 2018-12-14 宝生物工程株式会社 用于定量腺伴随病毒的方法
CA3205555A1 (en) 2014-04-25 2015-10-29 Genethon Treatment of hyperbilirubinemia
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
WO2016004319A1 (en) * 2014-07-02 2016-01-07 University Of Florida Research Foundation, Inc. Compositions and methods for purifying recombinant adeno-associated virus
CN107106689A (zh) 2014-11-05 2017-08-29 沃雅戈治疗公司 用于治疗帕金森病的aadc多核苷酸
CN112410338A (zh) 2014-11-14 2021-02-26 沃雅戈治疗公司 调节性多核苷酸
IL292999A (en) 2014-11-14 2022-07-01 Voyager Therapeutics Inc Compositions and methods of treating amyotrophic lateral sclerosis (als)
WO2016094783A1 (en) 2014-12-12 2016-06-16 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
CN107428799A (zh) * 2015-01-13 2017-12-01 阿尔法韦士曼公司 纯化腺相关病毒(AAV)及/或重组腺相关病毒(rAAV)之方法及其梯度和流通式缓冲液
EP3054007A1 (en) 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
EP3368054A4 (en) 2015-10-28 2019-07-03 Voyager Therapeutics, Inc. REGULATORY EXPRESSION USING THE ADENO-ASSOCIATED VIRUS (AAV)
EP3377042A4 (en) 2015-11-16 2019-05-29 The Research Institute at Nationwide Children's Hospital MATERIALS AND METHOD FOR THE TREATMENT OF TITIN-BASED MYOPATHIES AND OTHER TITINOPATHIES
WO2017100676A1 (en) * 2015-12-11 2017-06-15 The Trustees Of The University Of Pennsylvania Scalable purification method for aav8
LT3436593T (lt) 2016-03-28 2023-03-10 Ultragenyx Pharmaceutical Inc. Adenoviruso šiluminio inaktyvavimo būdai
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
KR20220108216A (ko) 2016-05-18 2022-08-02 보이저 테라퓨틱스, 인크. 헌팅톤 질환을 치료하기 위한 조성물 및 방법
SG11201809699XA (en) 2016-05-18 2018-12-28 Voyager Therapeutics Inc Modulatory polynucleotides
KR20190045174A (ko) * 2016-07-21 2019-05-02 스파크 테라퓨틱스, 인코포레이티드 재조합 아데노신 관련 바이러스(rAAV) 벡터를 고수율로 생산하기 위한 확장 가능한 고회수 방법 및 이에 의해 생산된 재조합 아데노-관련 바이러스(rAAV) 벡터
EP3510161A4 (en) 2016-08-23 2020-04-22 Akouos, Inc. COMPOSITIONS AND METHODS FOR TREATING PERSONAL HEARING LOSS IN A PERSON
CN110650673B (zh) 2016-08-30 2024-04-09 加利福尼亚大学董事会 用于生物医学靶向和递送的方法以及用于实践该方法的装置和系统
EP3293259A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
PE20191203A1 (es) 2016-09-12 2019-09-10 Genethon Variantes de alfa-glucosidasa acida y usos de las mismas
EP3293260A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
EP3293203A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
US11166915B2 (en) 2016-09-16 2021-11-09 Leukocare Ag Method for obtaining efficient viral vector-based compositions for vaccination or gene therapy
PT3534922T (pt) 2016-11-04 2024-06-07 Takeda Pharmaceuticals Co Formulações de vírus adenoassociado
US10626376B2 (en) 2016-11-14 2020-04-21 St. Jude Children's Research Hospital Method for isolating and purifying adeno-associated virus particles using salt
US10294452B2 (en) * 2016-11-22 2019-05-21 Dao-Yao He Lysis, extraction and purification of adeno-associated virus and adenovirus from host cells
EP3576796A1 (en) 2017-02-01 2019-12-11 Centre National De La Recherche Scientifique Particles and compositions comprising the same for transfection
WO2018162748A1 (en) 2017-03-10 2018-09-13 Genethon Treatment of glycogen storage disease iii
JP2020518259A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ハンチントン病治療組成物および方法
SG11201909870SA (en) 2017-05-05 2019-11-28 Voyager Therapeutics Inc Compositions and methods of treating amyotrophic lateral sclerosis (als)
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
JP7229989B2 (ja) 2017-07-17 2023-02-28 ボイジャー セラピューティクス インコーポレイテッド 軌道アレイガイドシステム
TWI832036B (zh) 2017-08-03 2024-02-11 美商航海家醫療公司 用於aav之遞送之組合物及方法
MX2020003042A (es) 2017-09-29 2020-11-18 Voyager Therapeutics Inc Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa.
EP4454654A3 (en) 2017-10-16 2025-02-19 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
US11434502B2 (en) 2017-10-16 2022-09-06 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (ALS)
CN120505370A (zh) * 2017-11-08 2025-08-19 诺华股份有限公司 制备病毒载体的手段和方法及其用途
AU2018378590A1 (en) * 2017-12-05 2020-06-25 Beacon Therapeutics Limited Formulation optimization for viral particles
AR114350A1 (es) 2018-01-31 2020-08-26 Res Institute At Nationwide Children’S Hospital Terapia genética para la distrofia muscular de cinturas del tipo 2c
CN120665951A (zh) 2018-02-07 2025-09-19 吉尼松公司 杂合调控元件
US20210010028A1 (en) 2018-03-06 2021-01-14 Voyager Therapeutics, Inc. Insect cell manufactured partial self-complementary aav genomes
US12129476B2 (en) 2018-04-27 2024-10-29 Voyager Therapeutics, Inc. Methods for measuring the potency of AADC viral vectors
EP3794126A1 (en) 2018-05-15 2021-03-24 Voyager Therapeutics, Inc. Compositions and methods for the treatment of parkinson's disease
EP3793686A1 (en) 2018-05-16 2021-03-24 Voyager Therapeutics, Inc. Aav serotypes for brain specific payload delivery
EP3793615A2 (en) 2018-05-16 2021-03-24 Voyager Therapeutics, Inc. Directed evolution of aav to improve tropism for cns
US12228571B2 (en) 2018-06-08 2025-02-18 Novartis Ag Cell-based assay for measuring drug product potency
CN113528510A (zh) 2018-06-29 2021-10-22 武汉纽福斯生物科技有限公司 治疗遗传性视神经病变的组合物和方法
WO2020006458A1 (en) 2018-06-29 2020-01-02 Research Institute At Nationwide Children's Hospital Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2a
CA3103963A1 (en) 2018-07-02 2020-01-09 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
AU2019299964A1 (en) * 2018-07-11 2021-01-21 Takeda Pharmaceutical Company Limited AAV compositions
JP2021530548A (ja) 2018-07-24 2021-11-11 ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics, Inc. 遺伝子治療製剤を生産するための系および方法
CA3107572A1 (en) 2018-08-08 2020-02-13 Genethon Mini-gde for the treatment of glycogen storage disease iii
US12612644B2 (en) * 2018-08-10 2026-04-28 Regenxbio Inc. Scalable method for recombinant AAV production
CA3109432A1 (en) 2018-08-20 2020-02-27 Wuhan Neurophth Biotechnology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
CN113383010B (zh) 2018-09-28 2025-09-09 沃雅戈治疗公司 具有经工程化改造的启动子的共济蛋白表达构建体及其使用方法
TW202035689A (zh) 2018-10-04 2020-10-01 美商航海家醫療公司 測量病毒載體粒子的效價及強度之方法
MX2021008542A (es) 2019-01-18 2021-11-12 Voyager Therapeutics Inc Métodos y sistemas para la producción de partículas de aav.
CA3131390A1 (en) 2019-02-26 2020-09-03 Research Institute Of Nationwide Children's Hospital Adeno-associated virus vector delivery of b-sarcoglycan and the treatment of muscular dystrophy
US20220162640A1 (en) 2019-04-08 2022-05-26 Genethon Hybrid promoters for muscle expression
KR20210153069A (ko) 2019-04-19 2021-12-16 제네똥 섬유아세포 성장 인자 23 관련 저인산혈증성 질환의 유전자 요법
WO2020214929A1 (en) * 2019-04-19 2020-10-22 Regenxbio Inc. Adeno-associated virus vector formulations and methods
WO2020223274A1 (en) 2019-04-29 2020-11-05 Voyager Therapeutics, Inc. SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS
AU2020319168B2 (en) 2019-07-25 2024-02-29 Novartis Ag Regulatable expression systems
US20220290182A1 (en) 2019-08-09 2022-09-15 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
US20220325250A1 (en) 2019-08-14 2022-10-13 Leukocare Ag Method for obtaining efficient compositions comprising viral vectors for vaccination or gene therapy
US11401530B2 (en) 2019-08-19 2022-08-02 The Catholic University Of America Bacteriophage-based artificial viruses for human genome remodeling
US11155835B2 (en) * 2019-08-19 2021-10-26 The Catholic University Of America Prokaryotic-eukaryotic hybrid viral vector for delivery of large cargos of genes and proteins into human cells
EP4488287A3 (en) 2019-08-21 2025-03-05 Research Institute at Nationwide Children's Hospital Adeno-associated virus vector delivery of alpha-sarcoglycan and the treatment of muscular dystrophy
WO2021041485A1 (en) 2019-08-26 2021-03-04 Voyager Therapeutics, Inc. Controlled expression of viral proteins
CN114728049A (zh) 2019-10-07 2022-07-08 再生生物股份有限公司 腺相关病毒载体药物组合物和方法
CN114555808A (zh) 2019-10-22 2022-05-27 吉尼松公司 嵌合多肽及其用途
WO2021078834A1 (en) 2019-10-22 2021-04-29 Genethon Chimeric acid-alpha glucosidase polypeptides and uses thereof
CN113025633B (zh) 2019-12-09 2024-08-27 武汉纽福斯生物科技有限公司 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
KR102167829B1 (ko) * 2020-02-10 2020-10-20 주식회사 이노테라피 아데노연관바이러스용 안정화제 및 이를 이용한 아데노연관바이러스의 안정화 방법
CN116096905A (zh) 2020-02-21 2023-05-09 阿库斯股份有限公司 用于治疗人受试者的非年龄相关性听力损伤的组合物和方法
WO2021236908A2 (en) 2020-05-20 2021-11-25 Biomarin Pharmaceutical Inc. Use of regulatory proteins for the production of adeno-associated virus
EP3913060A1 (en) 2020-05-22 2021-11-24 Genethon Vectors encoding a glucose-6-phosphatase (g6pase-a) for gene therapy
CN116096867A (zh) * 2020-06-02 2023-05-09 詹森生物科技公司 用于病毒纯化的材料和方法
WO2022032153A1 (en) 2020-08-06 2022-02-10 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
US20220040305A1 (en) * 2020-08-07 2022-02-10 Janssen Biotech, Inc. Formulations for highly purified viral particles
EP4200410A1 (en) 2020-08-24 2023-06-28 Genethon C-terminal truncated gde for the treatment of glycogen storage disease iii
US20230407328A1 (en) 2020-11-02 2023-12-21 Biomarin Pharmaceutical Inc. Process for enriching adeno-associated virus
EP4259790A1 (en) 2020-12-09 2023-10-18 Genethon Lysosomal acid lipase variants and uses thereof
EP4301768A2 (en) 2021-03-03 2024-01-10 Voyager Therapeutics, Inc. Controlled expression of viral proteins
US20240141378A1 (en) 2021-03-03 2024-05-02 Voyager Therapeutics, Inc. Controlled expression of viral proteins
WO2022208342A1 (en) * 2021-04-01 2022-10-06 Pfizer Inc. Pharmaceutical compositions containing adeno-associated viral vector
EP4333896A4 (en) * 2021-05-07 2025-03-19 Board of Regents, The University of Texas System Methods and compositions for transport, storage, and delivery of adeno-associated viral vectors and other molecules
CN117897492A (zh) 2021-08-04 2024-04-16 吉尼松公司 用于肌肉和cns中的基因表达的杂合启动子
US20240398985A1 (en) 2021-09-16 2024-12-05 Novartis Ag Novel transcription factors
US12285497B2 (en) 2021-10-15 2025-04-29 Research Institute At Nationwide Children's Hospital Self-complementary adeno-associated virus vector and its use in treatment of muscular dystrophy
US20250235554A1 (en) 2021-10-25 2025-07-24 Novartis Ag Methods for improving adeno-associated virus (aav) delivery
EP4511392A1 (en) 2022-03-17 2025-02-26 Innoskel Polynucleotides encoding the alpha-1 chain of human type ii collagen and methods of their use
WO2023175585A1 (en) 2022-03-17 2023-09-21 Innoskel Hybrid promoters and their use in osteolysis syndrome
JP2025517628A (ja) 2022-05-06 2025-06-10 ノバルティス アーゲー 新規の組換えａａｖ ｖｐ２融合ポリペプチド
CA3252764A1 (en) 2022-06-09 2023-12-14 Institut National de la Santé et de la Recherche Médicale GDE truncated at the N-terminal level for the treatment of type III glycogen storage disease
US20260085328A1 (en) 2022-09-08 2026-03-26 Voyager Therapeutics, Inc. Controlled expression of viral proteins
TW202426017A (zh) * 2022-11-24 2024-07-01 俄羅斯聯邦商拜奧卡德聯合股份公司 非包膜病毒的藥物組合物
CN121420060A (zh) 2023-06-29 2026-01-27 吉尼松公司 用于治疗糖原贮积病iii的n-端截短的糖原脱支酶
EP4606892A1 (en) 2024-02-23 2025-08-27 Merck Patent GmbH Methods for the production of viral particles

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE420977B (sv) * 1976-03-18 1981-11-16 Kabi Ab Forfarande for rening och isolering av hepatitvirus for vaccinframstellning
WO1998022588A2 (en) * 1996-11-20 1998-05-28 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
US7732129B1 (en) * 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6566118B1 (en) * 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
EP1080218A1 (en) * 1998-05-27 2001-03-07 University of Florida Method of preparing recombinant adeno-associated virus compositions by using an iodixanol gradient
CA2799545A1 (en) * 2000-03-07 2001-09-13 Merck Sharp & Dohme Corp. Adenovirus formulations
US6593123B1 (en) 2000-08-07 2003-07-15 Avigen, Inc. Large-scale recombinant adeno-associated virus (rAAV) production and purification
ATE360683T1 (de) * 2002-05-14 2007-05-15 Merck & Co Inc Verfahren zur reinigung von adenovirus

Also Published As

Publication number Publication date
EP1751275A4 (en) 2008-01-23
CA2569244C (en) 2017-02-14
US20060035364A1 (en) 2006-02-16
US7704721B2 (en) 2010-04-27
ES2932278T3 (es) 2023-01-17
EP1751275A1 (en) 2007-02-14
MX360727B (es) 2018-11-14
JP2019058177A (ja) 2019-04-18
JP5769650B2 (ja) 2015-08-26
CY1125798T1 (el) 2026-02-25
US20160083694A1 (en) 2016-03-24
WO2005118792A1 (en) 2005-12-15
MX2019006353A (es) 2022-06-27
MXPA06014030A (es) 2007-10-08
US20110076744A1 (en) 2011-03-31
EP3290513B1 (en) 2022-09-07
CA2569244A1 (en) 2005-12-15
JP2016195587A (ja) 2016-11-24
DK1751275T3 (da) 2017-11-27
JP2012143233A (ja) 2012-08-02
BRPI0511764B8 (pt) 2021-05-25
JP2014111625A (ja) 2014-06-19
HUE060433T2 (hu) 2023-03-28
EP4170024A1 (en) 2023-04-26
ES2647477T3 (es) 2017-12-21
US20170247664A1 (en) 2017-08-31
EP3290513A1 (en) 2018-03-07
BRPI0511764A (pt) 2008-01-08
JP2008501339A (ja) 2008-01-24
EP1751275B1 (en) 2017-08-16
HUE035418T2 (en) 2018-05-02
BRPI0511764B1 (pt) 2017-10-24
US9051542B2 (en) 2015-06-09

Similar Documents

Publication Publication Date Title
DK1751275T3 (da) Sammensætninger og fremgangsmåder til forebyggelse af aggregering af aav-vektorer
NO20200670A1 (no) Sammensetninger og fremgangsmåter for modulering av hemostase
DK1805312T3 (da) Fremgangsmåder og midler til fremstilling af hyaluronan
DK1730301T3 (da) Fremgangsmåder og sammensætninger til at analysere AHASL-gener
ITMI20041252A1 (it) Composizioni perfluoroelastomeriche
DK2203478T3 (da) Sammensætninger og fremgangsmåder til anvendelse af antistoffer mod sclerostin
DK1677735T3 (da) Fremgangsmåder og sammensætninger til modulering af adipocytfunktion
EP1799260A4 (en) ANTI-AMYLOID ANTIBODIES, COMPOSITIONS, TECHNIQUES AND USES
DK3308788T3 (da) Sammensætninger og fremgangsmåder til modulering af smn2-splejsning
DE602005026291D1 (de) Flüssige pestizidzusammensetzungen
FI20040156A0 (fi) Hydraulivasara
EP1788047A4 (en) WATER REPELLENT / OIL-REPELLING COMPOSITION
DK1713806T3 (da) Forbindelser og sammensætninger som proteinkinaseinhibitorer
DE602005005527D1 (de) Verschlussdüse
DK1858864T3 (da) Stabiliserede sammensætninger af flygtige alkyleringsmidler og fremgangsmåder til anvendelse deraf
DK2010501T3 (da) Imidazolbaserede forbindelser, sammensætninger omfattende disse og fremgangsmåder for deres anvendelse
EP1724635A4 (en) VIDEO PROJECTOR
EP1795833A4 (en) REFRIGERATION APPARATUS
DK3309233T4 (da) Sammensætninger omfattende hfc-1234yf og hfc-152a
JP2006522780A5 (ja) 液状形態及び凍結乾燥形態の免疫グロブリンｇ組成物用安定化配合物
DK1677949T3 (da) Antibelægningssammensætninger og fremgangsmåder til udvælgelse af disse
DE602004011525D1 (de) Armbandverschluss
ATE462692T1 (de) 3-amino-1-arylpropyl-indole als monoamin- wiederaufnahmehemmer
DK1817055T3 (da) Ovr110-antistofsammensætninger og fremgangsmåder til anvendelse heraf
DK1774566T3 (da) Sammensætninger til afgivelse af kviksölv og fremgangsmåde til fremstilling deraf